Natera Stock Soars 13.4% on 32.2% Revenue Surge

Natera's stock surged 13.4% in pre-market trading on August 8, 2025, driven by a significant increase in revenue that exceeded market expectations.

Natera reported a 32.2% year-over-year revenue growth in the second quarter of 2025, reaching $546.6 million. This growth was primarily driven by the company's Signatera MRD testing and the integration of AI technologies. The revenue figure surpassed analyst expectations by nearly $70.3 million, highlighting the company's strong performance in the oncology testing market.

In response to the impressive financial results, Natera raised its revenue guidance for the year to a range of $2.02 billion to $2.1 billion, marking a substantial increase from previous projections. The company also increased its gross margin guidance to 61% to 64%, reflecting improved operational efficiency and cost management.

The positive sentiment surrounding Natera's earnings report was further bolstered by a 51% surge in oncology tests, contributing to the company's record-breaking second-quarter results. The strong financial performance and optimistic outlook have positioned Natera as a leader in the oncology diagnostics market, with investors responding positively to the company's growth trajectory.